Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2380417 | 0.94 | ALDH1A1 (0.42) | TP53ALDH1A1SMN1; SMN2TPSAB1LMNA | |
| SCHEMBL23519429 | 0.92 | TP53 (0.37) | TP53ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL29603305 | 0.91 | TP53 (0.37) | TP53ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL29742315 | 0.88 | TP53 (0.43) | TP53ALDH1A1SMN1; SMN2TPSAB1LMNA | |
| SCHEMBL23031865 | 0.82 | KDM4E (0.36) | TP53SMN1; SMN2HTT | |
| SCHEMBL15326722 | 0.82 | TP53 (0.42) | TP53ALDH1A1SMN1; SMN2TPSAB1LMNA | |
| SCHEMBL16974355 | 0.80 | TP53 (0.40) | TP53ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL21300882 | 0.79 | ALDH1A1 (0.39) | TP53ALDH1A1SMN1; SMN2TPSAB1LMNA | |
| SCHEMBL14677758 | 0.77 | HTT (0.57) | ALDH1A1TPSAB1LMNAHTT | |
| SCHEMBL15748044 | 0.75 | CYP3A4 (0.55) | ALDH1A1TPSAB1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237116-A1 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | NOVARTIS AG | 2016-08-18 | — | — | US | disclosed |
| US-9359400-B2 | Site-specific chemoenzymatic protein modifications | NOVARTIS AG (CH) | 2016-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237116-A1 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | PTMS, TGM3, TGM1 | TP53 3892/4885ALDH1A1 3164/4885SMN1; SMN2 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.